Review · United States
Kisspeptin-10
Reviewed on
Approval and product status
No FDA-approved Kisspeptin-10 product was identified in the United States as reviewed August 30, 2026
Kisspeptin-10 has an FDA identity record, but that record is not an approval. FDA lists the substance in Category 2 for compounding. This category covers substances that may present significant safety risks. A product sold under the same name is not proven to match the material used in a study.
What was measured in people?
- Health results · Limited
- Small studies measured short-term hormone changes. They did not show better fertility, pregnancy, or lasting treatment results.
- Body changes · Moderate
- Studies in people measured how Kisspeptin-10 changed reproductive hormones during short research periods.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
FDA reports limited safety information for proposed injection routes and flags possible immune reactions, impurities, and product-quality problems. Small, short studies cannot show uncommon or long-term harms. This guide gives no dosing, injection, sourcing, or treatment instructions.
Still unknown: These studies do not show that Kisspeptin-10 improves fertility, causes pregnancy, treats low testosterone, increases muscle, lowers body fat, or improves libido. They do not establish long-term safety. Results from animals, Kisspeptin-54, or other kisspeptin drugs cannot fill these gaps.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Kisspeptin-10 is FDA-approved.”
Misleading. No FDA-approved product was identified. An FDA identity record does not mean approval. FDA also lists Kisspeptin-10 among substances that may present significant safety risks in compounding.
Applies to: United States status as reviewed August 30, 2026.
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
Small human studies measured short-term hormone changes. A 2026 study included 15 healthy men. It found changes in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone during controlled research. LH and FSH are body signals involved in reproduction. The study measured hormone activity, not a health benefit.
Read all Kisspeptin-10 fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 7 sources
- FDA review of Kisspeptin-10 for pharmacy compounding
U.S. Food and Drug Administration · FDA review · 2024
Source accessed
- FDA list of substances that may present compounding safety risks
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- FDA substance identity record for Kisspeptin-10
U.S. Food and Drug Administration · Reference · 2026
Source accessed
- Kisspeptin-10 and reproductive hormone release in healthy men
PubMed · Journal of Clinical Endocrinology and Metabolism · Human pharmacology · 2011
Source accessed
- Intermittent and continuous Kisspeptin-10 exposure in healthy men
PubMed · Journal of Clinical Endocrinology and Metabolism · Human pharmacology · 2026
Source accessed
- Direct human comparison of Kisspeptin-10 and Kisspeptin-54
PubMed · Journal of Clinical Endocrinology and Metabolism · Human pharmacology · 2015
Source accessed
- 2026 Prohibited List
World Anti-Doping Agency · Anti-doping · 2026
Source accessed